Compare Akerna Corp (KERN) With Other Cannabis Stocks

Head-to-head stock comparisons across price, valuation, financials, and growth metrics

Company

Akerna Corp (KERN)

Price

$47.37

Change

+6.26%

Market Cap

$4.82B

Sector

Ancillary

Ancillary Sector Peers

All Ancillary cannabis companies sorted by market capitalization. Click any ticker to see a detailed head-to-head comparison.

TickerNamePriceChange %MCap
SMGScotts Miracle-Gro$66.08+0.65%$3.91B
TPBTurning Point Brands$77.85-0.62%$1.49B
AGFYAgrify Corp$47.12+4.71%$94.2M
GRWGGrowGeneration$1.35-0.37%$81.1M
FORAForian Inc$2.15+0.23%$67.1M
GRAMFTPCO Holding (The Parent Company)$0.16-12.99%$45.7M
MAPSWM Technology (Weedmaps)$0.39-11.03%$42.0M
HYFMHydrofarm Holdings$1.010.00%$4.8M
FNNZFFinCanna Capital$0.00+38.10%$545.2K

Top Matchups by Market Cap

Companies closest to Akerna Corp in market capitalization — the most meaningful head-to-head comparisons.

SMGAncillary

Scotts Miracle-Gro

MCap: $3.91B

$66.08+0.65%
Compare
CURLFMSO

Curaleaf Holdings

MCap: $1.80B

$2.36+2.83%
Compare
IIPRREIT

Innovative Industrial Properties

MCap: $1.56B

$56.03+0.02%
Compare
GTBIFMSO

Green Thumb Industries

MCap: $1.54B

$6.56+7.01%
Compare
TPBAncillary

Turning Point Brands

MCap: $1.49B

$77.85-0.62%
Compare

Cross-Sector Comparisons

Top cannabis companies outside the Ancillary sector. Compare across different business models and market segments.

JAZZBiotech

Jazz Pharmaceuticals

MCap: $12.19B

$202.60+0.37%
Compare
CURLFMSO

Curaleaf Holdings

MCap: $1.80B

$2.36+2.83%
Compare
IIPRREIT

Innovative Industrial Properties

MCap: $1.56B

$56.03+0.02%
Compare
GTBIFMSO

Green Thumb Industries

MCap: $1.54B

$6.56+7.01%
Compare
TCNNFMSO

Trulieve Cannabis

MCap: $1.22B

$6.40+4.92%
Compare

Comparing KERN in the Cannabis Market

Akerna Corp (KERN) is a Ancillary-sector cannabis company trading at $47.37 per share with a market capitalization of $4.82B. Among its Ancillary peers, KERN ranks first by market cap, with trailing twelve-month revenue of $1.87B and a gross margin of 29.3%. The stock has moved +6.26% in the current session, trading on the NASDAQ exchange.

When comparing KERN against other cannabis stocks, investors should consider key financial metrics including price-to-sales ratio (14.6x), revenue growth (+6.20% YoY), and balance sheet strength (cash of $195.5M vs. debt of $572.3M). The comparison tables above allow you to evaluate Akerna Corp relative to 9 sector peers and leading companies across all cannabis sub-sectors, helping you identify which stocks offer better value, stronger growth, or more favorable risk profiles.

Frequently Asked Questions

How does KERN compare to other Ancillary stocks?+
Akerna Corp has a market cap of $4.82B, placing it among 10 companies in the Ancillary sector. Its price-to-sales ratio is 14.6x and its gross margin is 29.3%. Use the table above to compare these metrics against every Ancillary peer.
What is KERN's biggest competitor?+
By market capitalization, the closest comparable company is Scotts Miracle-Gro (SMG) with a market cap of $3.91B. Click the compare link to view a full head-to-head analysis.
Is KERN overvalued compared to its peers?+
Akerna Corp trades at a P/S ratio of 14.6x. Compare this to sector peers in the table above to determine relative valuation. A lower P/S may indicate relative value, while a higher P/S may reflect growth expectations.
Which cannabis stock has better margins than KERN?+
Akerna Corp has a gross margin of 29.3%. Among its Ancillary peers, 5 companies report higher gross margins. See the Sector Peers table for a full ranking.
Can I compare KERN to stocks in other cannabis sectors?+
Yes. The Cross-Sector Comparisons section above features top companies from sectors outside Ancillary. You can click any company to see a full side-by-side comparison with KERN covering price, valuation, financials, and growth metrics.

All KERN Comparisons

Every available head-to-head comparison for Akerna Corp.

Related Pages

Disclaimer: The comparison data on this page is for informational purposes only and does not constitute financial advice, investment recommendations, or an endorsement of any security. Cannabis stocks are highly volatile and subject to unique regulatory risks. Always conduct your own research and consult a licensed financial advisor before making investment decisions.Cannabismarketcap does not guarantee the accuracy or completeness of any data presented.